In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .
Developing a service model that integrates palliative care throughout cancer care: the time is now.
Palliative care is a fundamental component of cancer care . As part of the 2011 to 2012 Leadership Development Program ( LDP ) of the American Society of Clinical Oncology ( ASCO ) , a group of participants was charged with advising ASCO on how to develop a service model integrating palliative care throughout the continuum of cancer care . This article presents the findings of the LDP group . The group focused on the process of palliative care delivery in the oncology setting . We identified key elements for models of palliative care in various setting s to be potentially equitable , sustainable , feasible , and acceptable , and here we describe a dynamic model for the integrated , simultaneous implementation of palliative care into oncology practice . We also discuss critical considerations to better integrate palliative care into oncology , including raising consciousness and educating both providers and the public about the importance of palliative care ; coordinating palliative care efforts through strengthening affiliations and /or developing new partnerships ; prospect ively evaluating the impact of palliative care on patient and provider satisfaction , quality improvement , and cost savings ; and ensuring sustainability through adequate reimbursement and incentives , including linkage of performance data to quality indicators , and coordination with training efforts and maintenance of certification requirements for providers . In light of these findings , we believe the confluence of increasing importance of incorporation of palliative care education in oncology education , emphasis on value-based care , growing use of technology , and potential cost savings makes developing and incorporating palliative care into current service models a meaningful goal
In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .